Literature DB >> 7355922

Danazol binding and translocation of steroid receptors.

G C Chamness, R H Asch, C J Pauerstein.   

Abstract

Danazol, an isoxazol derivative of ethinyl testosterone which suppresses gonadotropin levels and acts as a weak androgen, is shown by competition studies to bind rat androgen receptor (Ki 10(-8M) and progestin receptor (Ki 10(-7)M) but not estrogen receptor. Effective antigonadotropin doses to the rat in vivo translocate only androgen receptor to target cell nuclei; nuclear receptor levels remain elevated more than 6 hours. The same translocation occurs when rat uteri are incubated with danazol in vitro, showing that the action of danazol is direct and probably does not require metabolic conversion of the drug.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7355922     DOI: 10.1016/0002-9378(80)90665-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  Proceedings of the Fiftieth Anniversary Meeting of the British Pharmacological Society, University of Oxford, 16-18 September 1981. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1981-12       Impact factor: 8.739

2.  Endometriosis--continuing conundrum.

Authors: 
Journal:  Br Med J       Date:  1980-10-04

Review 3.  A benefit-risk assessment of medical treatment for uterine leiomyomas.

Authors:  Vincenzo De Leo; Giuseppe Morgante; Antonio La Marca; Maria Concetta Musacchio; Massimo Sorace; Chiara Cavicchioli; Felice Petraglia
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  Effect of progestins, androgens, estrogens and antiestrogens on 3H-thymidine uptake by human endometrial and endosalpinx cells in vitro.

Authors:  J Neulen; B Wagner; M Runge; M Breckwoldt
Journal:  Arch Gynecol       Date:  1987

5.  Effects of an androgenic derivative on pre-established mammary tumours chemically induced in the rat.

Authors:  E Escrich; T Ribalta; J Muntané; M C Ruiz de Villa; J Murillo; S Saez
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.